Home Newsfeeds RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258

RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Sector Perform and lowers the price target from $268 to $258.

byBenzinga Newsdesk

February 1, 2023

1 minute read

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Sector Perform and lowers the price target from $268 to $258.

What’s Going On With Biogen Stock Thursday

By Henry Khederian

July 6, 5:08 PM

Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during

BIIB

Amtech Systems Announces CEO Transition; Michael Whang Stepped Down As Chief Executive Officer, Bob Daigle To Assume Role Effective August 8, 2023

By Benzinga Newsdesk

August 9, 4:54 PM

Amtech Systems, Inc. ("Amtech") (NASDAQ:ASYS), a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon

ASYS

What’s Next for Arm Holdings? Over 70 Engineers Gone in China as Global Strategy Shifts

By Anusuya Lahiri

December 18, 8:48 AM

Arm Holdings Plc (NASDAQ: ARM) recently let go of over 70 software engineers in China while it proposed relocating some of the roles outside the Asian nation.

ARM

Wells Fargo Maintains Overweight on Doximity, Lowers Price Target to $39

By Benzinga Newsdesk

February 10, 12:31 PM

Wells Fargo analyst Stan Berenshteyn maintains Doximity (NYSE:DOCS) with a Overweight and lowers the price target from $44 to $39.

DOCS

RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258

Related Posts

What’s Going On With Biogen Stock Thursday

Amtech Systems Announces CEO Transition; Michael Whang Stepped Down As Chief Executive Officer, Bob Daigle To Assume Role Effective August 8, 2023

What’s Next for Arm Holdings? Over 70 Engineers Gone in China as Global Strategy Shifts

Wells Fargo Maintains Overweight on Doximity, Lowers Price Target to $39